Corporate Presentation Actual results or events could differ materially from the plans, intentions and expectations disclosed or implied in the forward-looking statements the Company makes due to the risks and uncertainties inherent in the Company's business, including without limitation, the risks described in the Company's filings with the Securities and Exchange Commission ("SEC"). You are cautioned not to place undue reliance on these forward-looking statements, which represent the Company's views as of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an ...

Financial Position - As of March 31, 2025, Equillium, Inc. reported estimated cash, cash equivalents, and short-term investments of approximately $14.5 million[6]. Financial Reporting - The actual financial statements for the quarter ended March 31, 2025, are not yet available and will be subject to final adjustments[7]. - The preliminary financial data should not be viewed as a substitute for financial statements prepared in accordance with generally accepted accounting principles[7]. - The company has not audited or reviewed the preliminary financial data, which reflects information available only at this time[9]. - Risks related to preliminary financial results include potential discrepancies upon completion of financial closing procedures[9]. Forward-Looking Statements - Forward-looking statements in the report are based on current management expectations and reasonable assumptions, but actual results may differ materially[9]. - The company undertakes no obligation to update any forward-looking statements to reflect new information or events[9]. Regulatory Information - The company is registered with the SEC under the Securities Exchange Act of 1934[1]. - Equillium, Inc. is listed on the Nasdaq Capital Market under the symbol EQ[4]. Press Release - The report includes a press release dated April 24, 2025, which is incorporated by reference[9].

Shares of Equillium, Inc. (EQ) have been struggling lately and have lost 52.2% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road. While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future ea ...

Equillium, Inc. EQ released topline data on Thursday from the Phase 3 EQUATOR study. The study evaluated itolizumab in the first-line treatment of patients with acute graft-versus-host disease (aGVHD).The study results did not demonstrate a meaningful difference in complete response (CR) or overall response rate (ORR) at Day 29 between patients treated with itolizumab and placebo.However, the company said that statistically significant and clinically meaningful benefits in longer-term outcomes were achieved ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38692 EQUILLIUM, INC. (Exact name of registrant as specified in its Charter) Delaware 82-1554746 (State or other jurisdiction of inco ...

Financial Performance - Revenue for Q4 2024 was $4.4 million, down from $9.2 million in Q4 2023; full year revenue increased to $41.1 million from $36.1 million in 2023[6] - R&D expenses for Q4 2024 were $7.3 million, compared to $9.2 million in Q4 2023; full year R&D expenses slightly increased to $37.4 million from $37.0 million[7] - G&A expenses for Q4 2024 decreased to $1.8 million from $3.2 million in Q4 2023; full year G&A expenses were $11.9 million, down from $13.6 million[8] - Net loss for Q4 2024 was $5.8 million, or $(0.16) per share, compared to a net loss of $2.3 million, or $(0.07) per share in Q4 2023; full year net loss was $8.1 million, or $(0.23) per share, down from $13.3 million, or $(0.38) per share in 2023[9] Clinical Results - Itolizumab demonstrated a median duration of complete response of 336 days compared to 72 days for placebo, with a p-value of 0.017[4] - Itolizumab showed a median failure-free survival of 154 days versus 70 days for placebo, with a p-value of 0.043[4] Future Plans - The company expects FDA feedback on the Breakthrough Therapy designation request and Accelerated Approval pathway in May 2025[5] - The company plans to submit a biologics license application in the first half of 2026, pending positive FDA feedback and additional capital[2] Financial Position - Cash, cash equivalents, and short-term investments totaled $22.6 million as of December 31, 2024, down from $40.9 million as of December 31, 2023[11] - The total assets decreased to $25.6 million in 2024 from $50.5 million in 2023[18]

Core Viewpoint - Equillium, Inc. (EQ) has shown a recent downtrend, losing 5.3% over the past week, but a hammer chart pattern suggests a potential trend reversal due to increased buying interest [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottom in the stock price, suggesting that selling pressure may be exhausting [2][4]. - This pattern forms when there is a small candle body with a long lower wick, indicating that the stock opened lower, made a new low, but closed near its opening price, reflecting some buying interest [3][4]. - Hammer candles can appear on various timeframes and are utilized by both short-term and long-term investors [4]. Fundamental Analysis - Recent upward revisions in earnings estimates for EQ serve as a bullish indicator, correlating strongly with near-term stock price movements [6]. - Over the last 30 days, the consensus EPS estimate for the current year has increased by 29.4%, indicating that analysts expect better earnings than previously predicted [7]. - EQ holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [8].

Core Viewpoint - Equillium, Inc. (EQ) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on the consensus measure of EPS estimates from sell-side analysts, reflecting the company's changing earnings picture [1][2]. - Changes in earnings estimates are strongly correlated with near-term stock price movements, largely due to institutional investors using these estimates to calculate fair value [4]. Recent Performance and Projections - For the fiscal year ending December 2024, Equillium is expected to earn -$0.02 per share, representing a 94.7% change from the previous year's reported number [8]. - Over the past three months, the Zacks Consensus Estimate for Equillium has increased by 26.9%, indicating a positive trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7]. - Equillium's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Group 1: Momentum Investing Overview - Momentum investing deviates from the traditional "buy low and sell high" strategy, focusing instead on "buying high and selling higher" to maximize returns in a shorter time frame [1] - Fast-moving trending stocks can be appealing, but determining the right entry point is challenging, as these stocks may lose momentum if their valuations exceed future growth potential [2] Group 2: Investment Strategy and Stock Selection - Investing in bargain stocks that have recently shown price momentum can be a safer approach. The Zacks Momentum Style Score is useful for identifying strong momentum stocks, while the 'Fast-Paced Momentum at a Bargain' screen helps find attractively priced fast-moving stocks [3] - Equillium, Inc. (EQ) is highlighted as a strong candidate, with a four-week price change of 22.3%, indicating growing investor interest [4] - EQ has demonstrated positive returns over a longer time frame, gaining 20.7% over the past 12 weeks, and has a beta of 1.79, suggesting it moves significantly more than the market [5] Group 3: Performance Metrics and Valuation - EQ has a Momentum Score of B, indicating a favorable time to invest, and an upward trend in earnings estimate revisions has earned it a Zacks Rank 2 (Buy) [6][7] - The stock is trading at a Price-to-Sales ratio of 0.66, suggesting it is undervalued, as investors pay only 66 cents for each dollar of sales [7] Group 4: Additional Investment Opportunities - Besides EQ, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, presenting further investment opportunities [8] - The Zacks Premium Screens offer over 45 different strategies tailored to various investing styles, aiding in stock selection [9]